Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults

Cochrane Database of Systematic Reviews

Volumn 2012, Issue 9, 2012, Pages

  Eliakim Raz, Noa ^a   Robenshtok, Eyal ^a,b   Shefet, Daphna ^a   Gafter Gvili, Anat ^a   Vidal, Liat ^a   Paul, Mical ^b   Leibovici, Leonard ^a  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC PROPHYLAXIS; COMMUNICABLE DISEASE; DRUG COMBINATION; HOSPITALIZATION; HUMAN; META ANALYSIS; MICROBIOLOGY; MORTALITY; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT FAILURE;

ADULT; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; COMMUNITY-ACQUIRED INFECTIONS; DRUG THERAPY, COMBINATION; HOSPITALIZATION; HUMANS; PNEUMONIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT FAILURE;

EID: 84873036547     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004418.pub4     Document Type: Review

References (94)

1. Aubier M, Verster R, Regamey C, Geslin P, Vercken JB, Sparfloxacin European Study Group. Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults. Clinical Infectious Diseases 1998;26(6):1312-20.
2. Bohte R, van't Wout JW, Lobatto S, Blusse van Oud Alblas A, Boekhout M, Nauta EH, et al. Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia. European Journal of Clinical Microbiology and Infectious Diseases 1995;14(3):182-7.
3. Carbon C, Lephonte P, Petitpretz P, Chauvin JP, Hazebroucq J. Efficacy and safety of temafloxacin versus those of amoxicillin in hospitalized adults with community-acquired pneumonia. Antimicrobial Agents and Chemotherapy 1992;36(4):833-9.
4. Chuard C, Regamey C. Effect and tolerance of ofloxacin in bronchopulmonary infections in comparison with amoxicillin. Schweizerische Medizinische Wochenschrift 1989;119(52):1913-6.
5. Feldman C, White H, O'Grady J, Flitcroft A, Briggs A, Richards G. An open, randomised, multi-centre study comparing the safety and efficacy of sitafloxacin and imipenem/cilastatin in the intravenous treatment of hospitalised patients with pneumonia. International Journal of Antimicrobial Agents 2001;17(3):177-88.
6. Fourrier F, Chopin C, Lestavel P, Savage C. Initial antibiotherapy in severe bacterial bronchopneumopathies. Randomized study of a new quinolone: pefloxacin. La Presse Medicale 1986;15(26):1240.
7. Genné D, Siegrist HH, Humair L, Janin-Jaquat B, de Torrenté A. Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia. European Journal of Clinical Microbiology and Infectious Diseases 1997;16(11):783-8.
8. Gleadhill IC, Ferguson WP, Lowry RC. Efficacy and safety of ciprofloxacin in patients with respiratory infections in comparison with amoxycillin. Journal of Antimicrobial Chemotherapy 1986;18(Supp D):133-8.
9. Hatipoglu ON, Uysal S, Altiay G, Sut N, Tabakoglu E. The effect of addition of macrolide to a beta-lactam antibiotic on treatment success in patients with moderately severe community acquired pneumonia (Abstract). Proceedings of the European Respiratory Society Annual Congress; 2010 September 18-22; Barcelona, Spain. 2010.
10. Hirata-Dulas CA, Stein DJ, Guay DR, Gruninger RP, Peterson PK. A randomized study of ciprofloxacin versus ceftriaxone in the treatment of nursing home-acquired lower respiratory tract infections. Journal of the American Geriatrics Society 1991;39(10):979-85.
11. Hong-yun L, Chao Q, Qian L, Qun F. Observation of the therapeutic effects of gatifloxacin on community acquired pneumonia. Chinese Journal of Antibiotics 2007, (5).
12. Kalbermatter V, Bagilet D, Diab M, Javkin E. Oral levofloxacin versus intravenous ceftriaxone and amoxicillin/clavulanic acid in the treatment of community-acquired pneumonia that requires hospitalization. Medicina Clinica 2000;115(15):561-3.
13. Khan FA, Basir R. Sequential intravenous-oral administration of ciprofloxacin vs ceftazidime in serious bacterial respiratory tract infections. Chest 1989;96(3):453-6.
14. Kobayashi H, Takamura K, Kono K, Onodera S, Sasaki N, Nagahama F, et al. Comparison of DL-8280 and amoxicillin in the treatment of respiratory tract infections. Kansenshogaku Zasshi 1984;58(6):525-55.
15. Kohno S, Watanabe A, Aoki N, Niki Y, Kadota J, Fujita J, et al. Clinical phase III comparative study of intravenous levofloxacin and ceftriaxone in community-acquired pneumonia treatment. Japanese Journal of Chemotherapy 2011;59:32-45.
16. Leophonte P, File T, Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respiratory Medicine 2004;98(8):708-20.
17. Lode H, Garau J, Grassi C, Hosie J, Huchon G, Legakis N, et al. Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin. European Respiratory Journal 1995;8(12):1999-2007.
18. Miki F, Saito A, Tomizawa M, Nakayama I, Takebe K, Takashima T, et al. Comparative study of the effectiveness of enoxacin and amoxicillin in bacterial pneumonia by a double blind method. Kansenshogaku Zasshi 1984;58(10):1083-113.
19. Norrby SR, Petermann W, Willcox PA, Vetter N, Salewski E. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scandinavian Journal of Infectious Diseases 1998;30(4):397-404.
20. Peterson PK, Stein D, Guay DR, Logan G, Obaid S, Gruninger R, et al. Prospective study of lower respiratory tract infections in an extended-care nursing home program: potential role of oral ciprofloxacin. American Journal of Medicine 1988;85(2):164-71.
21. Jardim JR, Rico G, de la Roza C, Obispo E, Urueta J, Wolff M, et al. A comparison of moxifloxacin and amoxicillin in the treatment of community-acquired pneumonia in Latin America: results of a multicenter clinical trial. Archives de Bronchoneumologia 2003;39(9):387-93.
22. Petitpretz P, Arvis P, Marel M, Moita J, Urueta J, CAP5 Moxifloxacin Study Group. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest 2001;119(1):185-95.
23. Allegra L, Berni F, Boisisio E, Clini V, Dal Negro R, Damato S, et al. Efficacy of the teicoplanin-ciprofloxacin combination in high risk community acquired pneumonia: Comparison to ceftriaxone in a multicenter study. Internista 1995;31:39-43.
24. Montemurro L, Rizzato G, Multicenter Study Group. The teicoplanin-ciprofloxacin combination versus ceftriaxone in community acquired pneumonia of elderly and patients with underlying diseases. European Respiratory Journal 1993;7(Supp 18):170.
25. Rizzato G, Allegra L: Multicentre Italian Study Group (co-ordinated by Centro Thorax). Efficacy and tolerability of teicoplanin-ciprofloxacin combination in severe community-acquired pneumonia. Comparison with ceftriaxone in a multicentre Italian study. Clinical Drug Investigation 1997;14(5):337-45.
26. Romanelli G, Cravarezza P, Pozzi A, Franchino L, Ravizzola G, Zulli R, et al. Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy. Journal of Chemotherapy 2002;14(6):609-17.
27. Tremolieres F, de Kock F, Pluck N, Daniel R. Trovafloxacin versus high-dose amoxicillin (1g three times daily) in the treatment of community-acquired bacterial pneumonia. European Journal of Clinical Microbiology and Infectious Diseases 1998;17(6):447-53.
28. Tremolieres F, Mayaud C, Mouton Y, Weber P, Dellatolas F, Caulin E. Efficacy and safety of pristinamycin vs amoxicillin in community acquired pneumonia in adults. Pathologie-biologie (Paris) 2005;53(8-9):503-10.
29. Vanderdonckt J. Comparison of pefloxacin with ceftazidime in severe bronchopulmonary infections. Journal of Antimicrobial Chemotherapy 1990;26(Suppl B):111-6.
30. Vogel F, Lode H. The use of oral temafloxacin compared with a parenteral cephalosporin in hospitalized patients with pneumonia. Journal of Antimicrobial Chemotherapy 1991;28(Supp C):81-6.
31. Zeluff BJ, Lowe P, Koorhof HJ, Gentry LO. Evaluation of roxithromycin (RU-965) versus cephradine in pneumococcal pneumonia. European Journal of Clinical Microbiology and Infectious Diseases 1988;7(1):69-71.
32. Ailani RK, Agastya G, Ailani RK, Mukunda BN, Shekar R. Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia. Archives of Internal Medicine 1999;159(3):266-70.
33. Aubier M, Lode H, Gialdroni-Grassi G, Huchon G, Hosie J, Legakis N, et al. Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies. Journal of Antimicrobial Chemotherapy 1996;37(Suppl A):73-82.
34. Chokshi R, Restrepo MI, Weeratunge N, Frei CR, Anzueto A, Mortensen EM. Monotherapy versus combination antibiotic therapy for patients with bacteremic Streptococcus pneumoniae community-acquired pneumonia. European Journal of Clinical Microbiology and Infectious Diseases 2007;26(7):447-51.
35. Donowitz GR, Brandon ML, Salisbury JP, Harman CP, Tipping DM, Urick AE, et al. Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study. Clinical Therapeutics 1997;19(5):936-53.
36. Fass RJ, Plouffe JF, Russell JA. IV/oral ciprofloxacin vs ceftazidime in the treatment of serious infections. American Journal of Medicine 1989;87(5A):164-8.
37. File TM, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrobial Agents and Chemotherapy 1997;41(9):1965-72.
38. Fink MP, Snydman DR, Niederman MS, Leeper KV Jr, Johnson RH, Heard SO, et al. The Severe Pneumonia Study Group. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrobial Agents and Chemotherapy 1994;38(3):547-57.
39. Fong IW, Laforge J, Dubois J, Small D, Grossman R, Zakhari R, The Canadian Bronchitis Study Group. Clarithromycin versus cefaclor in lower respiratory tract infections. Clinical and Investigative Medicine. Médecine Clinique et Experimentale 1995;18(2):131-8.
40. Geijo Martinez MP, Diaz de Tuesta, Chow-Quan AM, Herranz CR, Gomez Criado C, Dimas Nunez JF, et al. Levofloxacin versus beta-lactamic therapy in community acquired pneumonia that requires hospitalisation [Levofloxacino frente a betalactamicos en el tratamiento de la neumonia adquirida en la comunidad con ingreso hospitalario]. Anales de Medicina Interna 2002;19(12):609-11.
41. Hagberg L, Torres A, van Rensburg D, Leroy B, Rangaraju M, Ruuth E. Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia. Infection 2002;30(6):378-86.
42. Hoepelman AI, Sips AP, van Helmond JL, van Barneveld PW, Neve AJ, Zwinkels M, et al. A single-blind comparison of three-day azithromycin and ten-day co-amoxiclav treatment of acute lower respiratory tract infections. Journal of Antimicrobial Chemotherapy 1993;31(Suppl E):147-52.
43. Katz E, Larsen LS, Fogarty CM, Hamed K, Song J, Choudhri S. Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy. Journal of Emergency Medicine 2004;27(4):395-405.
44. Khajotia R, Drlicek M, Vetter N. A comparative study of ofloxacin and amoxycillin/clavulanate in hospitalized patients with lower respiratory tract infections. Journal of Antimicrobial Chemotherapy 1990;26(Suppl D):83-91.
45. Kinasewitz G, Wood RG. Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia. European Journal of Clinical Microbiology and Infectious Diseases 1991;10(10):872-7.
46. Krumpe PE, Cohn S, Garreltes J, Ramirez J, Coulter H, Haverstock D, et al. Ciprofloxacin Study Group. Intravenous and oral mono- or combination-therapy in the treatment of severe infections: ciprofloxacin versus standard antibiotic therapy. Journal of Antimicrobial Chemotherapy 1999;43(Supp A):117-28.
47. Kuzman I, Dakovic-Rode O, Oremus M, Banaszak AM. Clinical efficacy and safety of a short regimen of azithromycin sequential therapy vs standard cefuroxime sequential therapy in the treatment of community-acquired pneumonia: an international, randomized, open-label study. Journal of Chemotherapy 2005;17(6):636-42.
48. Leophonte P, Veyssier P. Levofloxacin in the treatment of community-acquired pneumococcal pneumonia. La Presse Medicale 1999;28(36):1975-9.
49. Levine D, McNeil P, Lerner SA. Randomized, double-blind comparative study of intravenous ciprofloxacin versus ceftazidime in the treatment of serious infections. American Journal of Medicine 1989;87(5A):160-3.
50. Lode H, Wiley R, Hoffken G, Wagner J, Borner K, Lode H, et al. Prospective randomized controlled study of ciprofloxacin versus imipenem-cilastatin in severe clinical infections. Antimicrobial Agents and Chemotherapy 1987;31(10):1491-6.
51. Lode H, Wiley E, Olschewski P, Sievers H, Wintermantel M, Baetz R, et al. Prospective randomized clinical trials of new quinolones versus beta-lactam antibiotics in lower respiratory tract infections. Scandinavian Journal of Infectious Diseases 1990;68(Suppl):50-5.
52. Lode H, Aubier M, Portier H, Ortquist A, Sparfloxacin Study Group. Sparfloxacin as alternative treatment to standard therapy for community-acquired bacteremic pneumococcal pneumonia. Clinical Microbiology and Infection 1998;4(3):135-43.
53. Lode H, Magyar P, Muir JF, Loos U, Kleutgens K, International Gatifloxacin Study Group. Once-daily oral gatifloxacin vs three-times-daily co-amoxiclav in the treatment of patients with community-acquired pneumonia. Clinical Microbiology and Infection 2004;10(6):512-20.
54. Mendonca JS, Yamaguti A, Correa JC, Badaro R. Gatifloxacin in the treatment of community-acquired pneumonias: a comparative trial of ceftriaxone, with or without macrolides, in hospitalized adult patients with mild to moderately severe pneumonia. Brazilian Journal of Infectious Diseases 2004;8(1):90-100.
55. Mouton Y, Beuscart C, Leroy O, Ajana F, Charrel J, Groupe Multicentrique. Evaluation of ciprofloxacin versus amoxicillin + clavulanic acid or erythromycin for the empiric treatment of community-acquired pneumonia. Pathologie-Biologie 1991;39(1):34-7.
56. O'Doherty BO, Dutchman DA, Pettit R, Maroli A. Randomized, double blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia. Journal of Antimicrobial Chemotherapy 1997;40(Supp A):73-81.
57. Ott SR, Allewelt M, Lorenz J, Reimnitz P, Lode H. Moxifloxacin vs ampicillin/sulbactam in aspiration pneumonia and primary lung abscess. Infection 2008;36(1):23-30.
58. Peacock J Jr, Pegram SP, Weber SF, Leone PA. Prospective, randomized comparison of sequential intravenous followed by oral ciprofloxacin with intravenous ceftazidime in the treatment of serious infections. American Journal of Medicine 1989;87(5A):185S-90S.
59. Plouffe JF, Herbert MT, File TM Jr, Baird I, Parsons JN, Kahn JB, et al. Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Antimicrobial Agents and Chemotherapy 1996;40(5):1175-9.
60. Rahav G, Fidel J, Gibor Y, Shapiro M. Azithromycin versus comparative therapy for the treatment of community acquired pneumonia. International Journal of Antimicrobial Agents 2004;24(2):181-4.
61. Siami GA, Wilkins WT, Bess DT, Christman JW. Comparison of ciprofloxacin with imipenem in the treatment of severe pneumonia in hospitalised geriatric patients. Drugs 1995;49(Supp 2):436-8.
62. Sifuentes-Osornio J, Macias A, Amieva RI, Ramos A, Ruiz-Palacios GM. Intravenous ciprofloxacin and ceftazidime in serious infections. A prospective, controlled clinical trial with third-party blinding. American Journal of Medicine 1989;87(5A):202S-5S.
63. Snydman D, Fink F, Niederman M, Reinhart H. Treatment of severe pneumonia in hospitalised patients. Results of a multicentre trial comparing i.v. ciprofloxacin with imipenem/cilastatin. Drugs 1995;49(Supp 2):439-41.
64. Stocks JM, Wallace RJ Jr, Griffith DE, Garcia JG, Kohler RB. Ofloxacin in community-acquired lower respiratory infections. A comparison with amoxicillin or erythromycin. American Journal of Medicine 1989;87(6C):52-6.
65. Bhavnani SM, Ambrose PG. Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia. Diagnostic Microbiology and Infectious Disease 2008;60(1):59-64.
66. Torres A, Muir JF, Corris P, Kubin R, Duprat-Lomon I, Sagnier PP, et al. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. European Respiratory Journal 2003;21(1):135-43.
67. Trenholme GM, Schmitt BA, Spear J, Gvazdinskas LC. Randomized study of intravenous/oral ciprofloxacin versus ceftazidime in the treatment of hospital and nursing home patients with lower respiratory tract infections. American Journal of Medicine 1989;87(Supp 5A):116S-8S.
68. Welte T, Petermann W, Schurmann D, Bauer TT, Reimnitz P. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. Clinical Infectious Diseases 2005;41(12):1697-705.
69. Wollschlager CM, Raoof S, Khan FA, Guarneri JJ, LaBombardi V, Afzal Q. Controlled, comparative study of ciprofloxacin versus ampicillin in treatment of bacterial respiratory tract infections. American Journal of Medicine 1987;82(4A):164-8.
70. British Thoracic Society. BTS guidelines for the management of community acquired pneumonia in adults. Thorax 2001;56(Suppl 4:IV):1-64.
71. Donowitz G, Mandell G. Acute Pneumonia. In: Mandell GL, Bennet JE, Dolin R editor(s). Principles and Practice of Infectious Diseases. 5th Edition. Vol. 1, Philadelphia: Churchill Livingstone, 2000:717-43.
72. FDA. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf (accessed May 2010) (accessed May 2010).
73. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. New England Journal of Medicine 1997;336(4):243-50.
74. Hedlund J, Stralin K, Ortqvist A, Holmberg H. Swedish guidelines for the management of community-acquired pneumonia in immunocompetent adults. Scandinavian Journal of Infectious Diseases 2005;37:791-805.
75. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane-handbook.org 2011.
76. Iezzoni LI, Moskowitz MA. A clinical assessment of MedisGroups. JAMA 1988;260(21):3159-63.
77. Johansen HK, Jensen TG, Dessau RB, Lundgren B, Frimodt-Moller N. Antagonism between penicillin and erythromycin against Streptococcus pneumoniae in vitro and in vivo. Journal of Antimicrobial Chemotherapy 2000;46:973-80.
78. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
79. Levison M. Pneumonia, including necrotizing pulmonary infections (lung abscess). In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL editor(s). Harrison's Principles of Internal Medicine. 15th Edition. Vol. 2, New York: McGraw-Hill, 2001:1475-85.
80. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58(5):377-82.
81. Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, et al. BTS guidelines for the management of community acquired pneumonia in adults. Thorax 2009;64(Suppl 3):1-55.
82. Malhotra-Kumar S, Lammens C, Coenen S, Van Herck K, Goossens H. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet 2007;369(9560):482-90.
83. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH, The Canadian Community-Acquired Pneumonia Working Group. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clinical Infectious Diseases 2000;31:383-421.
84. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clinical Infectious Diseases 2007;44(Suppl 2):27-72.
85. Mills DG, Oehley MR, Arrol B. Effectiveness of beta-lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. BMJ 2005;330(7489):456.
86. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, et al. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. American Journal of Respiratory and Critical Care Medicine 2001;163(7):1730-54.
87. Oosterheert JJ, Bonten MJM, Hak E, Schneider MM, Hoepelman IM. How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community-acquired pneumonia? A systematic review. Journal of Antimicrobial Chemotherapy 2003;52(4):555-63.
88. Paul M, Nielsen AD, Gafter-Gvili A, Tacconelli E, Andreassen S, Almanasreh N, et al. The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis. European Respiratory Journal 2007 May 30 [Epub ahead of print].
89. Ross DB. The FDA and the case of Ketek. New England Journal of Medicine 2007;356(16):1601-4.
90. Soreth J, Cox E, Kweder S, Jenkins J, Galson S. Ketek - the FDA perspective. New England Journal of Medicine 2007;356(16):1675-6.
91. Woodhead M, Blasi F, Ewig S, Huchon G, Ieven M, Ortqvist A, et al. Guidelines for the management of adult lower respiratory tract infections. European Respiratory Journal 2005;26:1138-80.
92. Woodhead M, Blasi F, Ewig S, Huchon G, Leven M, Ortqvist A, et al. Guidelines for the management of adult lower respiratory tract infections. Clinical Microbiology infections 2011;17(6):1-24.
93. Robenshtok E, Shefet D, Gafter-Gvili A, Paul M, Vidal L, Leibovici L. Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD004418.pub3]
94. Shefet D, Robenshtok E, Paul M, Leibovici L. Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD004418.pub3]